{"article_title": "An Empty Obama-Clinton-Sanders Plan on Drug Costs", "article_keywords": ["presidentialcampaign", "sanders", "require", "drug", "research", "rd", "trail", "proposalsechoed", "costs", "plan", "release", "president", "obamaclintonsanders", "value"], "article_url": "http://www.wsj.com/articles/an-empty-obama-clinton-sanders-plan-on-drug-costs-1458601547", "article_text": "President Obama\u2019s latest budget includes proposals\u2014echoed or one-upped on the presidential-campaign trail by Bernie Sanders and Hillary Clinton\u2014that would require pharmaceutical companies to release data on the cost of research and development (R&D) and the extent of discounts offered to insurers for each drug brought to market. Yet the key numbers already are disclosed freely\u2014and we know how to get better value from medicines and improve their affordability to patients.\n\nThe company I lead, Lilly, discloses its annual...", "article_metadata": {"article.template": "snippet", "article.created": "2016-03-21T23:05:00.000Z", "article.section": "Opinion", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "John Lechleiter criticizes proposals by Hillary Clinton, Bernie Sanders and Barack Obama to mandate drug-by-drug data on R&D spending. It is all but impossible to properly allocate the money this way, and pointless.", "title": "An Empty Obama-Clinton-Sanders Plan on Drug Costs", "image": {"src": "https://si.wsj.net/public/resources/images/BN-NE446_Lechle_G_20160321123922.jpg", "alt": "An empty Obama-Clinton-Sanders plan on drug costs", "identifier": "https://si.wsj.net/public/resources/images/BN-NE446_Lechle_D_20160321123922.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10923506645052544897404581602700010540050&headline=An%20empty%20Obama-Clinton-Sanders%20plan%20on%20drug%20costs&weburl=http://www.wsj.com/articles/SB10923506645052544897404581602700010540050"}}, "page.site.product": "WSJ", "keywords": "plans,strategy,research,development,corporate,industrial news,political,general news,politics,international relations,domestic politics,commentaries,opinions,pharmaceuticals,health care,life sciences", "news_keywords": "plans,strategy,research,development,corporate,industrial news,political,general news,politics,international relations", "article.headline": "An empty Obama-Clinton-Sanders plan on drug costs", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-NE446_Lechle_E_20160321123922.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-NE446_Lechle_D_20160321123922.jpg"}}, "description": "John Lechleiter criticizes proposals by Hillary Clinton, Bernie Sanders and Barack Obama to mandate drug-by-drug data on R&D spending. It is all but impossible to properly allocate the money this way, and pointless.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10923506645052544897404581602700010540050&headline=An%20empty%20Obama-Clinton-Sanders%20plan%20on%20drug%20costs&weburl=http://www.wsj.com/articles/SB10923506645052544897404581602700010540050", "user.type": "nonsubscriber", "article.page": "Commentary", "page.content.format": "responsive", "article.summary": "John Lechleiter criticizes proposals by Hillary Clinton, Bernie Sanders and Barack Obama to mandate drug-by-drug data on R&D spending. It is all but impossible to properly allocate the money this way, and pointless.", "page.site": "wsj", "testkeys": "C", "article.published": "2016-03-21T23:05:00.000Z", "dj.asn": "i-4bd0", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "image_count": 1, "word_count": 778, "external_link_count": 2}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "John Lechleiter criticizes proposals by Hillary Clinton, Bernie Sanders and Barack Obama to mandate drug-by-drug data on R&D spending. It is all but impossible to properly allocate the money this way, and pointless.", "title": "An Empty Obama-Clinton-Sanders Plan on Drug Costs", "url": "http://www.wsj.com/articles/an-empty-obama-clinton-sanders-plan-on-drug-costs-1458601547", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-NE446_Lechle_G_20160321123922.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "John C. Lechleiter", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "An Empty Obama-Clinton-Sanders Plan on Drug Costs", "article.type": "Commentary (U.S.)", "article.id": "SB10923506645052544897404581602700010540050", "user.exp": "default", "article.updated": "2016-03-21T23:05:00.000Z"}, "article_summary": "Yet the key numbers already are disclosed freely\u2014and we know how to get better value from medicines and improve their affordability to patients.\nThe company I lead, Lilly, discloses its annual...\nPresident Obama\u2019s latest budget includes proposals\u2014echoed or one-upped on the presidential-campaign trail by Bernie Sanders and Hillary Clinton\u2014that would require pharmaceutical companies to release data on the cost of research and development (R&D) and the extent of discounts offered to insurers for each drug brought to market."}